increased arrhythmogenicity in the setting of ischemia through altered cardiac conduction. 23 GWAS in a 1,268 SCDs identified and replicated the association of the rs4665058 common variant near the BAZ2B gene (bromodomain adjacent zinc finger domain 2B), 9 with as yet unclear functional significance. GWAS of electrocardiographic phenotypes linked to SCD risk found the strongest association with the NOS1AP (nitric oxide synthase 1 adaptor protein) gene 24 that has been linked to the risk of SCD in the general population as well as in congenital LQTS. 25, 26 Repolarization reserve: An example of genetic susceptibility to SCD Acquired LQTS is an idiosyncratic and rare adverse drug reaction that causes both QT prolongation and torsades de pointes (TdP), the polymorphic ventricular tachycardia characteristic of congenital LQTS. It is an important issue in drug safety and development. A rare LQTS genetic variant is detected in approximately10% of cases. 27 Much of the risk associated with S1103Y in African Americans in the early study by Splawski et al. 19 was related to medications known to prolong the QT interval. S1103Y prolongs late sodium current that in turn delays cardiac repolarization. KCNE1-D85N, is another example of a common SNP associated with an eightfold increased risk of drug-induced TdP in people taking QT-prolonging drugs. 28 Noncoding SNPs of the NOS1AP gene were also linked to the risk of drug-induced TdP in patients taking amiodarone, a commonly used antiarrhythmic agent. 8 These data support the hypothesis of the "repolarization reserve," a physiologic redundancy of capacity to repolarize the myocardium. Overt congenital LQTS is caused by rare functionally severe mutations while some rare or common genetic variations underlie a concealed genetic reduction of repolarization reserve, which prolongs the QT interval to a minimal extent. 29 The risk of "acquired" LQTS increases with exposure to insults, such as QT-prolonging medications, hypokalemia, or subarachnoid hemorrhage, particularly as such factors may be additive. In addition, women tend to have longer QT intervals and are thus at higher risk for either congenital or acquired LQTS.
Implications for future research
Genetic testing due to SCD concern is relevant not only in suspected cardiomyopathy or arrhythmias but also in people with other disorders. The potential overlap with genetic risk in SUDEP remains to be explored. For example, the seizure-induced bradycardia, acidosis, and autonomic dysfunction may represent an insult to repolarization reserve. However, misdiagnosis of epilepsy also needs to be considered. Cerebral anoxia secondary to a cardiac arrhythmia may be responsible for the seizure phenotype, particularly in the young adult who dies after one, or only a few, seizures, or has exertion-related seizures. This clinical presentation of an arrhythmia syndrome must not be forgotten given the implications of risk to the family. Although only relevant to patients with some genetic epilepsies, there is also the possibility that the same genetic abnormality predisposing to epilepsy predisposes to SCD as discussed below. Finally, although molecular autopsy has started to be applied in SUDEP cases on a research basis, family assessment for SCD genetic risk may also be a good avenue to explore.
The Genetic Spectrum of SUDEP
The panel of candidate SUDEP genes has been growing rapidly, and discoveries have been facilitated by progress in the field of SCD and SIDS, and by translational research in sophisticated animal models.
Arrhythmia genes
The discovery of cardiac voltage-gated sodium channel SCN5A in brain limbic regions provided the first link between genetically predisposed cardiac arrhythmias and epilepsy. 30 Subsequent clinical case studies supported the concept of a combined neurocardiac phenotype triggered by mutations in ion channels dually expressed in the brain and in the heart. 31, 32 This was followed by the report of epilepsy, cardiac arrhythmias, and SUDEP in transgenic mice carrying the human knock-in mutations in the most common LQT gene, the potassium channel KCNQ1. 33 The observed model SUDEP event mirrored a previously described human case report, 34 and the study uncovered some of the candidate networks and mechanisms involved in the lethal epilepsy outcome. Consequently, a seizure phenotype was identified in 28% of cases with confirmed LQTS caused by pathogenic variants in the KCNH2, KCNQ1, and SCN5A genes, [35] [36] [37] and variants of suspected functional significance were uncovered in 10% of 48 SUDEP cases. 38 Yet, the molecular underpinnings of neurocardiac interactions extend beyond the LQT gene family; a catecholaminergic polymorphic ventricular tachycardia (CPVT) is a dysrhythmia presenting with stressinduced syncope 39 and a high 30-50% mortality rate before the age of 30 39 due to a defect in the ryanodine receptor (RYR2). 40 The mouse model carrying the human mutation R2474S displayed exercise-induced ventricular arrhythmia and early onset spontaneous convulsive seizures, and lethal arrhythmia triggered sudden death. 41 The combined phenotype of arrhythmias and seizures was also observed in 12 of 24 of Dutch CPVT families affected by RYR2 mutations 39 and a missense variant RYR2-G4936A was found in an 8-year-old SUDEP case with history of epilepsy and recurrent, exercise-induced syncope with normal resting electrocardiography (ECG). 42 The hyperpolarization-activated cyclic nucleotide-gated ion channels HCN1-4 are implicated in epilepsy and cardiac arrhythmias, owing to their involvement in the generation of the cation (Na+ and K+)-triggered I h depolarizing current that facilitates action potential and a spontaneous rhythmic activity in the neurons and pacemaking cardiomyocytes. [43] [44] [45] [46] [47] [48] The HCN2-deficient mouse displays absence epilepsy and sinus arrhythmia, 49 albeit without evidence of a reduced life span. A clinically confirmed phenotype of epilepsy and arrhythmia in humans has not yet been observed, although HCN coding variants of suspected functional significance were uncovered in a mutational screen of 48 SUDEP cases. 50 Therefore, the involvement of HCN channels in clinically manifest arrhythmia or epilepsy justifies the consideration of this gene family in candidate SUDEP genes.
Epilepsy genes
Many ion channel genes regulating the central control of cardiac and respiratory function are also expressed within the brain networks thought to underlie epilepsy. For example, the voltage-gated potassium channel KCNA1 is expressed in brain and in the vagus nerve. The Kcna1 null mice show seizures, cardiac arrhythmias, vagal hyperexcitability, and premature death. 51 This channel was also clinically validated in a SUDEP case affected by epileptic encephalopathy and suspected cardiac dysrhythmias carrying de novo and novel KCNA1 intragenic duplication. 52 The report of familial SUDEP in a kindred affected by the genetic epilepsy syndrome generalized epilepsy with febrile seizures plus (GEFS+) while segregating a novel variant in SCN1A gene brought attention to this sodium channel subunit, 53 a principal gene underlying the Dravet syndrome (DS). Patients with DS face an increased risk of premature mortality currently estimated to affect about 4-12% of children, [54] [55] [56] and they seem predisposed to autonomic dysfunction, as evidenced by depressed heart rate variability (HRV) 57, 58 and increased P-and QT-interval dispersion. 58 The Scn1a deficient models mirror the complex human phenotype, exhibiting spontaneous seizures, autonomic instability, and seizure-driven vagal activation preceding sudden death. 59, 60 Administration of parasympatholytics reduced the incidence of ictal bradycardia and SUDEP in the model. 60 A knock-in mouse model carrying the human mutation SCN1A-R1407X 61,62 displayed a 21% premature death rate, spontaneous seizures, and a prolonged QT interval due to the increased sodium channel-dependent cardiac current in cardiomyocytes. 62 Cardiac arrhythmias in this model often preceded apparent convulsive seizures, thus indicating that some SCN1A variants might predispose to sudden death through neurocardiac or sole cardiac mechanisms. 62 There is also experimental evidence that mortality risk in DS is influenced by the affected neuronal cell type and regionally specific differences in Scn1a brain expression; selective Na v 1.1 deficiency in inhibitory γ-aminobutyric acid (GABA)ergic neurons led to a more severe epileptic phenotype and early and frequent sudden death as compared to mice with constitutive Scn1a deficiency. 61 Scn1a deficiency restricted to forebrain excitatory neurons combined with global Na v 1.1 deficiency in inhibitory GABAergic neurons mitigated the seizure phenotype and lessened the incidence of model SUDEP. 61 The discoveries linking KCNA1 and SCN1A to SUDEP brought attention to other epilepsy genes. The SCN1B gene encodes a voltage-gated sodium channel (VGSC) β subunit critical for proper gating and cell surface expression of the VGSC complex. 63 SCN1B mutations are linked to GEFS+, temporal lobe epilepsy, as well as DS. [64] [65] [66] The Scn1b null mouse model displays spontaneous seizures, prolonged QT and RR intervals, and early mortality. 67, 68 Spontaneous epilepsy and >30% premature mortality was also observed in a mouse deficient in the glutamic acid decarboxylase isoform GAD65. 69 Confirmation of SCN1B and GAD65 in human SUDEP awaits discovery. Comprehensive genomic profiling is certain to facilitate the finding of novel molecular candidates as shown by the detection of a functionally active de novo variant in the SCN8A channel gene in a child affected by epileptic encephalopathy and SUDEP. [70] [71] [72] SUDEP was also reported in children affected by epilepsy due to variants in the KCNQ2 gene. 73 
Genes involved in respiration and arousal
Animal models [74] [75] [76] [77] and translational human studies 78 have uncovered the critical role of 5-hydroxytryptamine (5-HT) in respiration and arousal 79 and they are discussed in detail elsewhere in this supplement. Mice deficient in the 5-HT2c receptor develop epileptic seizures and are susceptible to premature death, 74 and the genetically engineered Lmx1bf/f/p mice depleted of all 5-HT neurons have severe apnea, hypoventilation, diminished hypercapnic response, compromised arousal from sleep, and premature mortality. 80 There are known alterations in expression levels of several 5-HT receptors in the DBA/2 audiogenic seizure model with ictally induced respiratory arrest and sudden death. 81 These discoveries have led to early pharmacologic intervention exploring the possible beneficial effect of the widely available serotonin reuptake inhibitors (SSRIs) on SUDEP risk. Administration of SSRI in the DBA/1 model ameliorated ictally induced respiratory arrest and death and the effect was age dependent. 82, 83 Clinical observations reflected the animal data, as people with epilepsy chronically exposed to SSRIs were less likely to experience profound oxygen desaturation with partial, but not secondarily generalized, seizures. 78 
Complex genetics of human SUDEP
There is growing evidence that variant functional properties along with complex genetic interactions influence the phenotypic expressions of cardiac arrhythmias, 12,84,85 epilepsy, 52, 86, 87 and SUDEP. 52 Although SCN8A gain-of-function mutations are implicated in epileptic encephalopathies and SUDEP, 70, 86, 88 animal models carrying loss-of-function variants exhibit milder seizure phenotype. 71, 72 In addition, Kcna1 SUDEP model crossed with a Cacna1a absence seizure mouse has mild seizure phenotype and improved survival. 89 Furthermore, modulation of neuronal hyperexcitability and premature mortality extends beyond genetic interactions of the ion channel network; the deficiency of the microtubulebinding protein tau in the Kcna1 knockout mouse not only reduced the seizure frequency and severity, but also improved survival. 90 A human example of genomic complexity in SUDEP was recently illustrated by a pediatric case with DS, frequent ictal apnea, and suspected cardiac arrhythmias. 52 Detailed genomic analysis uncovered interesting combinations of SNPs and copy number variants in genes expressed in both neurocardiac and respiratory control pathways, including SCN1A, KCNA1, RYR3, and HTR2C.
Understanding SUDEP Genetics in Populations-The Australian Experience
Tu et al. 38, 50 carried out a retrospective review of postmortem reports performed at a single forensic center between 1993 and 2009, identifying 68 cases: the cause of death was "SUDEP" or "possible SUDEP" in 22 and 46 cases, respectively. Postmortem blood was available in 48 cases, and DNA was screened for variants in the most common LQTS genes, 38 KCNQ1, KCNH2, and SCN5A, as well in the HCN gene family. 43, 44, 50 There was a KCNH2 Arg176Trp and Arg1047Leu missense variation in one and four SUDEP cases, respectively, a single Ala572Asp, Pro1090Leu, and Pro2006Ala missense variation in SCN5A in three SUDEP cases 38 and nine nonsynonymous HCN genic variants. 50 The Arg176Trp variant in KCNH2 is a nonconservative substitution in a highly conserved N-terminal region of the protein. According to bioinformatic (in silico) analysis, it is probably damaging. The KCNH2 176Trp allele is a common founder mutation associated with a prolonged QT interval in Finnish LQTS families. [91] [92] [93] It is also reported in a case of sudden unexplained death. 94 In vitro functional studies have shown that the Arg176Trp substitution alters ion channel function, causing accelerated channel deactivation and reduced potassium current density, resulting in a prolonged QT interval. 92 Collectively, these results implicate the KCNH2 Arg176Trp variant in prolongation of the QT interval, a likely trigger of a fatal arrhythmia in the SUDEP case, a 35-year-old man, reportedly diagnosed with epilepsy 5 years prior to death who had 10 episodes requiring hospitalization; neuropathology examination reported left hippocampal sclerosis. KCNH2 Arg1047Leu is a common variant found in 2.9% SUDEP cases (2.9%). One patient with SUDEP, a 52-yearold woman with a history of controlled epilepsy, carried the KCNH2 Arg1047Leu polymorphism in addition to the rare SCN5A Ala572Asp variant that has been reported previously in LQTS and in a case of sudden cardiac death. 95, 96 Neuropathology reported microdysgenesis in the left hippocampus. As discussed earlier, 7 it is plausible that the combined effect of these two protein-changing variants raised the risk of sudden death in this patient. SCN5A Pro2006Ala is a rare variant with a minor allele frequency (MAF) of 0.1%, reported previously in a case of unexplained cardiac arrest and LQTS. 97, 98 This variant was found in a 43-year-old man who died of SUDEP who had nocturnal seizures. The SCN5A Pro1090Leu variation shows ethnically variable MAF of 0.008% in European and African ancestry but 2% in an Asian subpopulation. It is considered an Asian-specific polymorphism. 99, 100 This variant was found in a 23-year-old from China with a history of poorly controlled epilepsy. HCN2 Phe738Cys is a nonconservative substitution in the carboxyl-cytoplasmic tail of the HCN2 protein, predicted by in silico to be possibly damaging. It was detected in a 52-year-old man, a carrier of the common KCNH2 Arg1047Leu polymorphism. The patient had infrequent seizures since the age of 16 years. HCN2 Pro802Ser is a nonconservative substitution in the carboxyl-cytoplasmic tail, predicted to be benign. It was detected in a 43-year-old man, also a carrier of the SCN5A Pro2006Ala variant, and who had a witnessed nocturnal seizure. HCN4 Gly973Arg is a nonconservative substitution found in a 44-year-old man with reportedly regular seizures prior to death.
Genetic analysis of the Australian SUDEP cohort supports the hypothesis that genes encoding K + , Na + , and Ca 2+ ion channels expressed both in neuronal and/or cardiac cells are likely to play an important role in the predisposition of epilepsy patients to SUDEP. 38, 50 It remains to be determined whether these ion channel variants are the genetic cause in some SUDEP cases or an accompanying risk factor in the sudden death of patients with epilepsy. The variants may act in isolation or require the presence of a second genetic factor or environmental influence, such as uncontrolled seizures, QT-prolonging AEDs, or noncompliance with AED therapy, to predispose epilepsy patients to malignant arrhythmias and sudden death. Screening candidate genes, one at a time, limits the scope of genetic studies. Furthermore, although postmortem blood offers an ideal source of DNA for genetic studies in SUDEP, it is of finite supply, and not always available. Recent major advances in DNA enrichment and "next-generation" sequencing technologies have provided a new and powerful approach to identify mutations responsible for genetic disorders. The ability to enrich and sequence all of the protein coding exons (the exome) reduces the target region to 1.5% of the genome, while retaining the sequences most likely to harbor the majority of variations with high penetrance. 101 
Genetics of SUDEP: Tissue Collection and Utilization
Genetic variation likely contributes to SUDEP risk, but it is unclear how such variation might best be identified; in particular what samples are needed, what methods and analyses might be used, and how potential genetic leads might be followed through.
DNA collection for genetic studies in epilepsy is well established. Worldwide, tens of thousands of DNA samples have now been collected, and many thousands genotyped 102 or exome sequenced. The genetic study of SUDEP clearly provides a different level of challenge, as SUDEP cannot be predicted and there is no "target" population, although some groups of patients might be considered at greater risk. Collection in life for SUDEP studies is challenging, although greater SUDEP awareness 103 could facilitate this. Collection after SUDEP is difficult to systematize. The logistic difficulties of obtaining postmortem material require an awareness of the need and the processes, appropriate consent, and an established infrastructure. Up until now, most genetic studies of SUDEP have been of single cases or small series. In view of this, Klassen et al. 104 investigated the possibility of using other sources for DNA in SUDEP. They were able to extract DNA that could be used for at least some studies from blood spots on Guthrie cards, buccal scrapes on Guthrie cards, and from fingernails. In the field of oncology, it is now a well-established practice to undertake candidate gene or genome-wide whole exome sequencing from formalin-fixed paraffinembedded samples, including brain. This has opened up large archival collections for research.
Advancing technology now allows for genetic studies using ever-smaller samples of DNA. A recent pathologic study of 143 archived brain samples 105 established the potential of this approach which in future could use prospectively collected samples from both postmortem and surgical cases, SUDEP and otherwise, to generate a regulated and approved resource for further research into, among other areas, SUDEP.
Clinical Implications
It is difficult at this time to translate genetic advances into pragmatic advice for patients, particularly as SUDEP tragically affects a wide range of individuals with epilepsy. Indeed there may be distinct separate populations at risk of SUDEP, with potentially different mechanisms. One group of individuals, typically young adults, with no significant prior known comorbidities and infrequent seizures, who die suddenly might represent a different population from those with severe epilepsy who manifest with frequent generalized convulsions. In the former group, genetic susceptibility to epilepsy may be associated with a genetic susceptibility to sudden cardiac death. 106 In the latter group, there may be complex additive interactions between polygenetic factors, medication, and the consequences of frequent severe seizures. In SUDEP, there is currently no evidence to guide practice for routine genetic testing. However, with genetic screening for long-QT-associated mutations, once confined to the research laboratory, now clinically available as diagnostic tests, 107 any SUDEP case should have a careful review of the family history, and any concern should result in a molecular genetics study.
The first priority in epilepsy practice is to ensure that patients do have epilepsy, rather than a cardiac disorder. 108 All new epilepsy patients must undergo a careful cardiac history and a detailed family history, particularly asking about sudden cardiac death and unexplained deaths in infancy. All patients, indeed anyone who has a blackout, should have an electrocardiogram (Table 1) . Modern automated ECG machines may help screen for cardiac disorders, but a cardiologist, experienced in the relevant abnormalities, must review any abnormalities identified as potentially abnormal. Epilepsy patients with an abnormal or equivocal ECG study, or any suspicious family history, should undergo specialist cardiac review. A specialist cardiac review should also be arranged for any patients who report suspicious symptoms including exercise-related seizures, or where there is witnessed profound pallor during seizures. Such patients should be assessed for possible prolonged monitoring, ideally with an implantable event recorder (IER) ( Table 1 ). It is likely that at present barriers to arranging such specialist assessments result more from lack of awareness among neurologists rather than from resistance from cardiology services.
Even in expert hands, however, spotting QT abnormalities is problematic, most cardiologists miss them, 109 and IER is costly. 110 It is important that all those who care for people with epilepsy be aware that not only might potentially life-threatening cardiac disorders mimic epilepsy, 111 but also patients with epilepsy might be at increased risk of concurrent cardiac arrhythmias.
Developing the hypothesis that there might be (at least) two distinct populations within SUDEP cases, and considering those with frequent generalized seizures despite medication, the use of IER technology needs to be assessed looking for potential markers of cardiac instability. It has long been recognized that some patients have identifiable cardiac abnormalities in the interictal state, 112 and during seizures, 113, 114 including varying degrees and types of heart block. In addition, such patients may have disturbances of autonomic function, both when untreated, 115 and also possibly associated with treatment 116 ; withdrawal of treatment may exacerbate these abnormalities. 117 These interictal and ictal cardiac disturbances might be of particular significance in those with severe medically intractable epilepsies, and in this group, therefore, the results of prolonged cardiac monitoring might be used to guide drug choices, including nonepilepsy drugs, could help with counseling about other potentially modifiable risk factors, and might result in implantable devices to protect selected patients. 113 These proposals represent significant changes to current routine practice, and require an increased awareness of the risks of SUDEP for patients. Highlighting these risks to patients has implications. 103 Furthermore, the proposals require increased engagement among neurologists regarding the need for review of cardiac risk factors. An informal survey of United Kingdom cardiac electrophysiologists by one of the authors (PC) suggests that cardiologists already acknowledge the need to investigate such patients. Many young adults who die of SUDEP are not dissimilar to young adults who die of SCD. Increased public awareness of SCD has improved its prevention. It is hoped that increased public awareness of the risks of epilepsy might do the same for SUDEP.
Key Points

•
Evidence suggests likely genomic complexity and a degree of overlap among among sudden cardiac death, sudden infant death syndrome, and SUDEP
In some genetic epilepsies, a mutation may also predispose to sudden death, whereas in acquired epilepsies, coexisting genetic variants may increase susceptibility 
